The effect of drug treatment on neurogenesis in Parkinson's disease

Movement Disorders

Volumn 26, Issue 1, 2011, Pages 45-50

  O'Sullivan, Sean S ^a,b   Johnson, Mary ^c   Williams, David R ^d   Revesz, Tamas ^b   Holton, Janice L ^b   Lees, Andrew J ^a,b   Perry, Elaine K ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d ALFRED HOSPITAL   (Australia)

Author keywords

Neurogenesis; Neuroprotection; Parkinson's disease; Stem cells

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BENZATROPINE; CITALOPRAM; DOSULEPIN; FLUOXETINE; IMIPRAMINE; LEVODOPA; LOFEPRAMINE; OLANZAPINE; ORPHENADRINE; OXYBUTYNIN; PAROXETINE; RNA BINDING PROTEIN; RNA BINDING PROTEIN MUSASHI1; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIHEXYPHENIDYL; UNCLASSIFIED DRUG; VENLAFAXINE;

ADULT; AGED; ARTICLE; AUTOPSY; BRAIN REGION; BRAIN TISSUE; CELL ACTIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFECT; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; NEUROPATHOLOGY; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; REGRESSION ANALYSIS; SUBVENTRICULAR ZONE;

AGED; ANTIPARKINSON AGENTS; CELL DIFFERENTIATION; CEREBRAL VENTRICLES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LEVODOPA; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; NEURAL STEM CELLS; NEUROGENESIS; PARKINSON DISEASE; POSTMORTEM CHANGES; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RNA-BINDING PROTEINS;

EID: 79951473139     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23340     Document Type: Article

References (33)

1. Greffard S, Verny M, Bonnet AM, et al. Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch Neurol 2006; 63: 584-588.
2. Geraerts M, Krylyshkina O, Debyser Z, Baekelandt V. Concise review: therapeutic strategies for Parkinson disease based on the modulation of adult neurogenesis. Stem Cells 2007; 25: 263-270.
3. Chojnacki AK, Mak GK, Weiss S. Identity crisis for adult periventricular neural stem cells: subventricular zone astrocytes, ependymal cells or both? Nat Rev Neurosci 2009; 10: 153-163.
4. Johansson CB, Momma S, Clarke DL, Risling M, Lendahl U, Frisen J. Identification of a neural stem cell in the adult mammalian central nervous system. Cell 1999; 96: 25-34.
5. Coskun V, Wu H, Blanchi B, et al. CD133+ neural stem cells in the ependyma of mammalian postnatal forebrain. Proc Natl Acad Sci U S A 2008; 105: 1026-1031.
6. Gould E, Reeves AJ, Graziano MS, Gross CG. Neurogenesis in the neocortex of adult primates. Science 1999; 286: 548-552.
7. Jin K, Wang X, Xie L, et al. Evidence for stroke-induced neurogenesis in the human brain. Proc Natl Acad Sci U S A 2006; 103: 13198-13202.
8. Gleason D, Fallon JH, Guerra M, Liu JC, Bryant PJ. Ependymal stem cells divide asymmetrically and transfer progeny into the subventricular zone when activated by injury. Neuroscience 2008; 156: 81-88.
9. Jin K, Galvan V, Xie L, et al. Enhanced neurogenesis in Alzheimer's disease transgenic (PDGF-APPSw, Ind) mice. Proc Natl Acad Sci U S A 2004; 101: 13363-13367.
10. Li B, Yamamori H, Tatebayashi Y, et al. Failure of neuronal maturation in Alzheimer disease dentate gyrus. J Neuropathol Exp Neurol 2008; 67: 78-84.
11. Hoglinger GU, Rizk P, Muriel MP, et al. Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci 2004; 7: 726-735.
12. Winner B, Lie DC, Rockenstein E, et al. Human wild-type alpha-synuclein impairs neurogenesis. J Neuropathol Exp Neurol 2004; 63: 1155-1166.
13. Ziabreva I, Ballard C, Johnson M, et al. Loss of Musashi1 in Lewy body dementia associated with cholinergic deficit. Neuropathol Appl Neurobiol 2007; 33: 586-590.
14. Kaneko Y, Sakakibara S, Imai T, et al. Musashi1: an evolutionally conserved marker for CNS progenitor cells including neural stem cells. Dev Neurosci 2000; 22: 139-153.
15. Kanemura Y, Sakakibara S, Okano H. Identification of Musashi1-positive cells in human normal and neoplastic neuroepithelial tissues by immunohistochemical methods. Methods Mol Biol 2002; 198: 273-281.
16. Sakakibara S, Imai T, Hamaguchi K, et al. Mouse-Musashi-1, a neural RNA-binding protein highly enriched in the mammalian CNS stem cell. Dev Biol 1996; 176: 230-242.
17. Seigel GM, Hackam AS, Ganguly A, Mandell LM, Gonzalez-Fernandez F. Human embryonic and neuronal stem cell markers in retinoblastoma. Mol Vis 2007; 13: 823-832.
18. Okano H, Imai T, Okabe M. Musashi: a translational regulator of cell fate. J Cell Sci 2002; 115(Pt 7): 1355-1359.
19. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, Fourth ed. Washington: American Psychiatric Association; 2000.
20. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 745-752.
21. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47: 1113-1124.
22. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-259.
23. Petrie A, Sabin C. Confidence intervals. In: Medical statistics at a glance, Third ed. Oxford: Wiley-Blackwell; 2009. p 35.
24. Coronas V, Bantubungi K, Fombonne J, Krantic S, Schiffmann SN, Roger M. Dopamine D3 receptor stimulation promotes the proliferation of cells derived from the post-natal subventricular zone. J Neurochem 2004; 91: 1292-1301.
25. Freundlieb N, Francois C, Tande D, Oertel WH, Hirsch EC, Hoglinger GU. Dopaminergic substantia nigra neurons project topographically organized to the subventricular zone and stimulate precursor cell proliferation in aged primates. J Neurosci 2006; 26: 2321-2325.
26. Malberg JE, Duman RS. Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacology 2003; 28: 1562-1571.
27. Abdipranoto A, Wu S, Stayte S, Vissel B. The role of neurogenesis in neurodegenerative diseases and its implications for therapeutic development. CNS Neurol Disord Drug Targets 2008; 7: 187-210.
28. Perera TD, Coplan JD, Lisanby SH, et al. Antidepressant-induced neurogenesis in the hippocampus of adult nonhuman primates. J Neurosci 2007; 27: 4894-4901.
29. Reif A, Fritzen S, Finger M, et al. Neural stem cell proliferation is decreased in schizophrenia, but not in depression. Mol Psychiatry 2006; 11: 514-522.
30. Hetzel W. Post-mortem modifications of the ependyma of the lateral ventricular wall. Acta Neuropathol 1980; 51: 15-22.
31. Murer MG, Dziewczapolski G, Menalled LB, et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 1998; 43: 561-575.
32. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351: 2498-2508.
33. Olanow CW. Can we achieve neuroprotection with currently available anti-parkinsonian interventions? Neurology 2009; 72(7 suppl): S59-S64.